MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehz372

Медицинская библиотека · European heart journal · 2019

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.

Urban Philip, Mehran Roxana, Colleran Roisin, Angiolillo Dominick J, Byrne Robert A, Capodanno Davide, Cuisset Thomas, Cutlip Donald, Eerdmans Pedro, Eikelboom John, Farb Andrew, Gibson C Michael, Gregson John, Haude Michael, James Stefan K, Kim Hyo-Soo, Kimura Takeshi, Konishi Akihide, Laschinger John, Leon Martin B, Magee P F Adrian, Mitsutake Yoshiaki, Mylotte Darren, Pocock Stuart, Price Matthew J, Rao Sunil V, Spitzer Ernest, Stockbridge Norman, Valgimigli Marco, Varenne Olivier, Windhoevel Ute, Yeh Robert W, Krucoff Mitchell W, Morice Marie-Claude

СтатьяПоддержка исследования: вне правительства СШАConsensus StatementПеревод пока не подготовлен

Аннотация

Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention-related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention.

Для цитирования: Urban Philip, Mehran Roxana, Colleran Roisin, Angiolillo Dominick J, Byrne Robert A, Capodanno Davide, Cuisset Thomas, Cutlip Donald, Eerdmans Pedro, Eikelboom John, Farb Andrew, Gibson C Michael, Gregson John, Haude Michael, James Stefan K, Kim Hyo-Soo, Kimura Takeshi, Konishi Akihide, Laschinger John, Leon Martin B, Magee P F Adrian, Mitsutake Yoshiaki, Mylotte Darren, Pocock Stuart, Price Matthew J, Rao Sunil V, Spitzer Ernest, Stockbridge Norman, Valgimigli Marco, Varenne Olivier, Windhoevel Ute, Yeh Robert W, Krucoff Mitchell W, Morice Marie-Claude. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.. European heart journal. 2019. DOI: 10.1093/eurheartj/ehz372.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.